NCT06822413 Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
| NCT ID | NCT06822413 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Cancer Diagnosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2025-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2022-09-01 with a primary completion date of 2025-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are: * Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk. * Identifying which model is more adaptable to the Raman spectrum * Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.
Eligibility Criteria
Inclusion Criteria: * Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer. * Patients in normal physiological conditions without any malignant tumors or precancerous lesions. * Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments. * Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease. Exclusion Criteria: * Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time * Post-cancer treatment patients.
Contact & Investigator
Kefeng Ding, MD
STUDY CHAIR
Department of Colorectal Surgery, The Second Hospital of Zhejiang University School of Medicine
Frequently Asked Questions
Who can join the NCT06822413 clinical trial?
This trial is open to participants of all sexes, studying Cancer Diagnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06822413 currently recruiting?
Yes, NCT06822413 is actively recruiting participants. Contact the research team at 1821286450@qq.com for enrollment information.
Where is the NCT06822413 trial being conducted?
This trial is being conducted at Nanchang, China, Nanchang, China, Shanghai, China, Hangzhou, China.
Who is sponsoring the NCT06822413 clinical trial?
NCT06822413 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The principal investigator is Kefeng Ding, MD at Department of Colorectal Surgery, The Second Hospital of Zhejiang University School of Medicine. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.